I think this is a clever approach to producing a vaccine that would seem more cost-effective than the present Elan vaccine. While the authors claim that their vaccine is highly antigenic, it is hard to know how it would compare to the Elan vaccine without a direct comparison. Clearly this is another viable route to producing anti-Aβ antibodies in vivo.

View all comments by Dave Morgan